Jun. 6 at 11:44 PM
$IOVA So we are going to combo with these drug peeps ... Food for thought 🤔........Analysts currently project that Keytruda sales in 2027 will likely be in the range of
$32–34 billion globally, making it one of the highest-selling drugs in the world. Most forecasts show continued growth through 2027 before the major patent cliff begins around 2028–2029.
Some recent projections and commentary:
Evaluate Pharma projects Keytruda sales peaking near
$32.7 billion in 2026, with growth continuing into 2027–2028.
Analysts cited in 2025–2026 industry reports estimate a peak around
$33–34 billion annually before biosimilar competition starts reducing revenue after patent expiration.
Merck’s quarterly 2026 results continue to show strong momentum, with Keytruda growing about 12% year-over-year and already generating over
$8 billion per quarter.
A reasonable Wall Street consensus estimate for 2027 is therefore approximate 38 Billion
